Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol

Autor: Morten C. Moe, Rowan Thomas Faber, Øystein Kalsnes Jørstad
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
medicine.medical_specialty
Time Factors
Visual acuity
genetic structures
Bevacizumab
Fundus Oculi
Recombinant Fusion Proteins
Visual Acuity
Angiogenesis Inhibitors
Treat and extend
03 medical and health sciences
0302 clinical medicine
Ranibizumab
Ophthalmology
medicine
Humans
Macula Lutea
Prospective Studies
Fluorescein Angiography
Prospective cohort study
Treatment resistant
Aged
Aflibercept
Drug Substitution
business.industry
General Medicine
Macular degeneration
medicine.disease
eye diseases
Receptors
Vascular Endothelial Growth Factor
Treatment Outcome
030104 developmental biology
Intravitreal Injections
Wet Macular Degeneration
030221 ophthalmology & optometry
Female
sense organs
medicine.symptom
business
Tomography
Optical Coherence
Follow-Up Studies
medicine.drug
Zdroj: Acta Ophthalmologica. 95:460-463
ISSN: 1755-375X
Popis: Purpose To study the effects of converting to aflibercept in accordance with a treat and extend (T&E) strategy in eyes with treatment resistant exudative age-related macular degeneration (AMD). Methods Two-year prospective study of eyes with exudative AMD and persistent macular fluid despite monthly treatment with ranibizumab or bevacizumab. Eyes were converted to 2.0 mg aflibercept in accordance with a T&E protocol. Results Fifty eyes from 47 patients were included. At baseline, the mean central retinal thickness (CRT) was 273 μm and mean best-corrected visual acuity (BCVA) 0.25 logarithm of the minimal angle of resolution (logMAR). The mean number of aflibercept injections the first year was 9.2. After 1 year, there was a reduction in mean CRT to 228 μm (p
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje